CN107298660A - The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer - Google Patents
The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer Download PDFInfo
- Publication number
- CN107298660A CN107298660A CN201610236731.5A CN201610236731A CN107298660A CN 107298660 A CN107298660 A CN 107298660A CN 201610236731 A CN201610236731 A CN 201610236731A CN 107298660 A CN107298660 A CN 107298660A
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- bases
- formation iii
- iii
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses 2 (5 bromine 4 (base of 4 cyclopropyl naphthalene 1) 4H 1,2, the base sulfenyl of 4 triazole 3) acetic acid S configuration axial chirality enantiomers crystal formation III, it is radiated using CuK α, X-ray powder diffraction spectrum for being represented with 2 θ angles at least has diffraction maximum at 6.04 ° ± 0.2 °, 7.88 ° ± 0.2 °, 11.04 ° ± 0.2 °, 15.78 ° ± 0.2 °, 16.36 ° ± 0.2 °, 16.84 ° ± 0.2 °, 18.18 ° ± 0.2 ° and 19.86 ° ± 0.2 °.Compared to amorphous form, crystal formation III stability is good, moist almost without drawing, and crystal form purity is high, is easy to medicine manufacture, storage and transports.
Description
Technical field
The invention belongs to pharmaceutical field, and in particular to medicine Lesinurad (i.e. 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalenes -1-
Base) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid) and axial chirality enantiomer crystal formation, more particularly to S configurations enantiomer crystal formation III
And its application in field of medicaments.
Background technology
Ardea Biosciences companies have developed a kind of new URAT1 inhibitor lesinurad, and its structure shown in formula I, is changed
Scientific name：2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid or 2- [[5- bromo- 4- (4- cyclopropyl
- 1- naphthalenes) -4H-1,2,4- triazole -3- bases] thio] acetic acid, CAS：878672-00-5.Lesinurad is a kind of rush homaluria oral medicine,
The patient with gout of hyperuricemia is treated by the sub- URAT1 of the uric acid transporter for suppressing kidney proximal tubule.
Chinese patent application 201510918016.5 discloses the lesinurad axial chirality enantiomters as shown in Formula II and formula III：
There is significant activity difference in two kinds of axial chirality enantiomters, R the or S configuration enantiomers disclosed in the patent application
Exist with amorphous form.In research process, the inventors discovered that 2- (5- bromo- 4- (the 4- cyclopropyl that amorphous form is present
Naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid axial chirality enantiomer existing defects in terms of stability, such as thermodynamics are not
The problems such as stabilization, poor fluidity, strong hygroscopicity, the preparation and storage of this drug bring certain difficulty.Therefore, it is badly in need of out
Crystal formation of the hair with stability is used as drug crystal forms form.
The content of the invention
In order to overcome the drawbacks described above of amorphous R- and S- configurations lesinurad axial chirality enantiomers, the present invention is for them
Crystal formation studied, develop a kind of crystal formation III of the good S configuration enantiomers of stability.
Therefore, it is an object of the present invention to provide the crystal formation III of the lesinurad axial chirality enantiomers of S configurations shown in formula III.
It is another object of the present invention to provide above-mentioned crystal formation III preparation method.
A further object of the present invention is that providing above-mentioned crystal formation III is preparing for treating tissue uric acid level abnormal condition
Purposes in medicine.
Pharmaceutical compositions of the above-mentioned crystal formation III as active component is included it is yet a further object of the present invention to provide a kind of.
To reach above-mentioned purpose, the present invention provides following technical scheme.
1. the S configuration axles of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid shown in formula III
The crystal formation III of chiral enantiomer：
The X-ray powder diffraction spectrum that it is radiated using CuK α, represented with 2 θ angles at least 6.04 ° ± 0.2 °,
7.88 ° ± 0.2 °, 11.04 ° ± 0.2 °, 15.78 ° ± 0.2 °, 16.36 ° ± 0.2 °, 16.84 ° ± 0.2 °, 18.18 ° ± 0.2 ° and 19.86 ° ± 0.2 °
There is diffraction maximum in place.
2. the crystal formation III of above-mentioned 1, wherein, also at least 2 θ values be 10.30 ° ± 0.2 °, 13.44 ° ± 0.2 °, 16.00 ° ± 0.2 °,
17.44 ° ± 0.2 °, 18.98 ° ± 0.2 °, 20.84 ° ± 0.2 °, 21.86 ° ± 0.2 °, 22.98 ° ± 0.2 °, 23.76 ° ± 0.2 ° and 24.32 ° ± 0.2 °
There is diffraction maximum in place.
3. preferably, the crystal formation III of above-mentioned 1, its at least 2 θ values be 6.04 ° ± 0.1 °, 7.88 ° ± 0.1 °, 11.04 ° ± 0.1 °,
There is diffraction maximum at 15.78 ° ± 0.1 °, 16.36 ° ± 0.1 °, 16.84 ° ± 0.1 °, 18.18 ° ± 0.1 ° and 19.86 ° ± 0.1 °.
4. preferably, the crystal formation III of above-mentioned 1 has the X-ray powder substantially identical with X-ray powder diffraction figure shown in Fig. 1
Last diffraction pattern.Without limitation and preferably, the crystal formation III described in above-mentioned 1 or 3, it is also at least in 2 θ values
10.30°±0.1°、13.44°±0.1°、16.00°±0.1°、17.44°±0.1°、18.98°±0.1°、20.84°±0.1°、21.86°±0.1°、
There is diffraction maximum at 22.98 ° ± 0.1 °, 23.76 ° ± 0.1 ° and 24.32 ° ± 0.1 °.
5. further, the crystal formation III of above-mentioned 1, wherein, the fusing point summit measured by differential scanning calorimetry (DSC)
It is worth for 106.4 DEG C.
6. further, the crystal formation III of above-mentioned 1, wherein, its thermogravimetric analysis (TGA) figure is as shown in figure 3, in room temperature extremely
Substantially massless is lost in the range of 150 DEG C.
7. a kind of method for preparing above-mentioned 1-6 crystal formation III, comprises the following steps：By unbodied 2- (5- bromo- 4- (4- rings third
Base naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid S configuration axial chiralities enantiomer add dimethylbenzene, toluene or two
The in the mixed solvent of toluene and hexamethylene, in 30~70 DEG C, preferably 35~60 DEG C, more preferably 40~50 DEG C heating for dissolving, system
Into saturated solution, cool, be preferably cooled to 0~20 DEG C of precipitation crystal, or stand precipitation crystal, produce crystal formation III.
Preferably, when dissolving unbodied S configurations axial chirality enantiomer using mixed solvent, dimethylbenzene：Other solvents
Volume ratio is 20~100：1.
Further, after cooling crystallization, the crystal formation III solids obtained by preferred pair filtering or centrifugation are dried, such as dried.
Drying temperature is 30~90 DEG C, preferably 30~70 DEG C, more preferably more preferably 40~60 DEG C, 40~50 DEG C.
8. above-mentioned 1-6 crystal formation III can be used for preparing medicine, the medicine is used to treat the abnormal illness of tissue uric acid level.
9. preferably, above-mentioned illness may be selected from gout, hyperuricemia, reduction serum uric acid etc..
10. based on the purposes of above-mentioned 8 or 9, the present invention can provide a kind of pharmaceutical composition, it includes the crystalline substance described in 1-6
Type III is used as active component.
Preferably, aforementioned pharmaceutical compositions are except the crystal formation III of therapeutically effective amount, also comprising at least one pharmaceutical excipient or
Pharmaceutical carrier.Preferably, the excipient be wetting agent, dispersant, pH adjusting agent, antioxidant, filler, diluent,
Lubricant, solubilizer, suspending agent, flavouring, adhesive, disintegrant, osmotic pressure regulator, flocculant, antiplastering aid,
One or more in suspending agent, emulsifying agent and preservative.
The present invention research show, 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazoles shown in unbodied formula III
- 3- bases sulfenyl) the S configuration axial chiralities enantiomer of acetic acid has and draws moist, and crystal formation III is then moist almost without drawing, therefore more
There is stability, and with preferable heat endurance, be easy to medicine manufacture, storage and transport.
Brief description of the drawings
Fig. 1 is the S configuration axial chirality enantiomers of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid
Crystal formation III X-ray powder diffraction figure (XPRD figures).
Fig. 2 is the S configuration axial chirality enantiomers of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid
Crystal formation III differential scanning calorimetry figure (DSC figures).Abscissa is temperature (DEG C)；Ordinate is heat flow (W/g).
Fig. 3 is the S configuration axial chirality enantiomers of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid
Crystal formation III thermogravimetric analysis figure (TGA figures).Abscissa is temperature (DEG C)；Ordinate is weight conservation rate (%).
Fig. 4 is the S configuration axial chirality enantiomers of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid
Absolute configuration illustraton of model.
Embodiment
Below in conjunction with specific embodiment and accompanying drawing, the invention will be further described.It should be understood that these embodiments are only used for
The bright present invention rather than limitation the scope of the present invention.Based on the embodiment in the present invention, those of ordinary skill in the art are not having
There is the every other embodiment made and obtained under the premise of creative work, belong to the scope of protection of the invention.
Addition, content and the concentration of many kinds of substance is referred to herein, wherein described percentage composition, unless otherwise indicated,
All refer to weight/mass percentage composition.
In embodiments of the invention, illustrated if do not made for reaction temperature or operation temperature, the temperature is usual
Refer to room temperature (20-25 DEG C).
Herein, (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid, the 2- (bromo- 4- (4- of 5-
Cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid S (structure) profile shafts chiral enantiomer, lesinurad S (structure)
Type enantiomer refers both to same compound, i.e., the compound shown in formula III.
Herein, the S configuration axial chirality enantiomers of amorphous form and the S configuration axial chirality enantiomers of crystal formation III forms
Chemical structural formula is all shown in formula III, but physical aspect is different.
In the present invention, term " axial chirality enantiomer ", " enantiomer ", " axial chirality enantiomers ", " axial chirality is different
Structure body " and " enantiomers " represent identical meaning.
Some chemical substances, due to affected by various factors, make intramolecular or intermolecular bonding mode change in crystallization,
Cause molecule or atom to arrange different in lattice vacancy, form different crystal structures.The different crystal forms of same medicine outward appearance,
Might have in terms of solubility, fusing point, dissolution rate, biological effectiveness it is dramatically different so that have impact on the stability of medicine,
Bioavilability and curative effect, this kind of phenomenon show particularly evident in terms of oral solid formulation.Drug crystal forms are influence medicines
One of quality, key factor of clinical efficacy and safety, therefore to the research of drug crystal forms, it is possible to find be conducive to playing medicine
The medicine advantage crystal formation of thing effect, while determine preparation process according to the characteristics of crystal formation, be effectively ensured production batch between medicine etc.
Effect property etc. is formulation scientist recipe development, the design of new drug formulation, the optimization of production technology, Drug's control and
Reference is provided in terms of clinical drug effect.
Crystal formation can be characterized by X-ray powder diffraction (XPRD) spectrogram, the XPRD figures of different crystal forms be it is different,
The diffraction maximum represented with 2 θ angles or the position of absworption peak and/or relative intensity (I/I0) can change.
The S configuration axial chiralities pair of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid of the present invention
The crystal formation III of body X-ray powder diffraction figure is reflected, the diffraction maximum position i.e. θ (°) of the angle of diffraction 2, interplanar distance is shown as
Diffraction maximum relative intensity (I/I0), it is summarized in table 1.
The crystal formation III of the Lesinurad of table 1 S configuration axial chirality enantiomers X-ray powder diffraction result
It is well known that same a kind of crystal formation sometimes, under different test conditions, X-ray powder diffraction figure can be slightly different.
The factor of influence X-ray powder diffraction figure effect has：The purity of crystal, crystallization degree, the size of powder sample itself particle,
Specimen holder filling powder sample amount, powder packing surface smoothness residing into specimen holder etc..
In a preferred embodiment, crystal formation III has the X-ray powder substantially identical with X-ray powder diffraction figure shown in Fig. 1
Last diffraction pattern.
It should be understood that 2 θ values of X-ray powder diffraction figure can be varied slightly between machine or between sample, its numerical value can
About 0.2 unit (°), or about 0.1 unit (°) of difference can be differed, therefore cited numerical value can not be construed to
Absolute value.It shall again be understood that the equally possible difference about 5% of the size of diffraction maximum relative intensity, or difference about 4%,
Either difference about 3% or difference about 2%, or difference about 1%, therefore the XRPD marks being included in the present invention
Line (trace) intensity is illustrative, is not meant for definitely comparing.
As preferred embodiment, 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- base sulphur that the present invention is provided
Base) acetic acid S configuration axial chirality enantiomers the crystal formation III x-ray powders that are radiated, represented with 2 θ angles using CuK α
Difraction spectrum at least 6.04 ° ± 0.1 °, 7.88 ° ± 0.1 °, 11.04 ° ± 0.1 °, 15.78 ° ± 0.1 °, 16.36 ° ± 0.1 °, 16.84 ° ± 0.1 °,
There is diffraction maximum at 18.18 ° ± 0.1 ° and 19.86 ° ± 0.1 °.More preferably X-ray powder diffraction spectrum at least 2 θ values be 6.04 °,
There is diffraction maximum at 7.88 °, 11.04 °, 15.78 °, 16.36 °, 16.84 °, 18.18 ° and 19.86 °.
Further, as another preferred embodiment, the above-mentioned crystal formation III that provides of the present invention using CuK α radiation, with
The X-ray powder diffraction spectrum that 2 θ angles are represented also at least 2 θ values be 10.30 ° ± 0.1 °, 13.44 ° ± 0.1 °, 16.00 ° ± 0.1 °,
17.44 ° ± 0.1 °, 18.98 ° ± 0.1 °, 20.84 ° ± 0.1 °, 21.86 ° ± 0.1 °, 22.98 ° ± 0.1 °, 23.76 ° ± 0.1 ° and 24.32 ° ± 0.1 °
There is diffraction maximum in place.More preferably X-ray powder diffraction spectrum also at least 2 θ values be 10.30 °, 13.44 °, 16.00 °, 17.44 °,
There is diffraction maximum at 18.98 °, 20.84 °, 21.86 °, 22.98 °, 23.76 ° and 24.32 °.
In addition, the present invention is also analyzed described novel crystal forms by differential canning calorimetry, differential scanning is being used
When Calorimetric Techniques are analyzed, show as in the presence of 1 endothermic peak existing in heating rate is 10 DEG C per minute of DSC collection of illustrative plates
At 106.4 DEG C, its spectrogram is substantially as shown in Figure 2.It should be understood that and X-ray powder diffraction figure numerical value may have deviation that there is phase
Like situation, the numerical value cited in differential canning calorimetry can not be construed to absolute value.
When referring to data in collection of illustrative plates and/or figure, term " diffraction maximum " refers to that those skilled in the art will not belong to background and make an uproar
The characteristic peak of sound.
Term " relative intensity " refers to that the intensity at intensity highest peak in all diffraction maximums of X-ray powder diffraction figure is 100%
When, the ratio of the intensity at other peaks and the intensity at intensity highest peak.
It should be understood that herein when stating numerical characteristics, term " about " or " about " refer to that this represented number can be with
There are ± 5%, ± 4%, ± 3%, ± 2% or ± 1% error range or domain of walker.
Term " substantially identical " refers at least 70% in X-ray powder diffraction figure, at least 80%, at least 90%, at least 95%,
Or at least 99% peak is appeared in given exemplary X-ray powder diffraction figure.
Crystal formation III of the present invention be it is essentially pure, term " essentially pure " refer to crystal formation III substantially free of
There are other crystal formations or amorphous form (or amorphous form) and/or other materials lesinurad such as shown in Formula II
R- configuration axial chirality enantiomers, the other materials refer to producing the crystal formation III processes and production amorphous form
Lesinurad S configuration axial chirality enantiomers during the impurity that brings.Preferably, crystal formation III purity is with percentage by weight
At least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 98% or at least 99% is calculated as, more preferably
For 100%.Except this main crystal formation, a small amount of other crystal formations, amorphous form and lesinurad shown in Formula II can also be mixed
R- configuration axial chirality enantiomers, but their percentage by weight less than 20%, less than 10%, less than 5%, less than 3%, be less than
1%th, less than 0.5%, less than 0.1% or less than 0.01%.
Term " essentially free of other crystal formations " refers to that the contents of the other crystal formations percentage by weight in crystal is less than 20%,
Or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.
The hygroscopicity (drawing moist) of medicine is to influence a key factor of stability of crystal form.In the present invention, term " is inhaled
It is moist " it is identical with " drawing moist ", " drawing wet " meaning.Determined, can be used for by drawing moist experiment, i.e. water sucting isotherm
Determine the relative stability region of polymorphic or monocrystalline type medicine particularly hydrate.
2010 editions annex of Chinese Pharmacopoeia are to medicine draws moist test guideline：Deliquescence：Absorb enough moisture formation liquid；
It is great to draw moist：Draw wet weightening and be not less than 15%；It is moist with drawing：Draw wet weightening 2%-15%；Slightly draw moist：Draw wet
Increase weight 0.2%-2%；Nothing is moist almost without drawing：Draw wet weightening and be less than 0.2%.
The present invention has carried out lesinurad S configurations enantiomer crystal formation III and without fixed in the room temperature environment of 80% relative humidity
Shape draws moist comparative study, as a result shows：Within 14 days, it is amorphous have draw moist；And crystal formation III is wet almost without drawing
Property.It can be seen that crystal formation III draws moist small than amorphous, with more stability.
In the pharmaceutical composition of the present invention, including pharmaceutical excipient or pharmaceutical carrier.In the present invention, the excipient is
Refer to the additives in pharmaceutical preparation in addition to main ingredient, alternatively referred to as auxiliary material.Such as the binder in tablet, filler, disintegration
Agent, lubricant；Base portion in semisolid preparation ointment, creme；Preservative, antioxidant in liquid preparation, rectify
Taste agent, aromatic, cosolvent, emulsifying agent, solubilizer, osmotic pressure regulator, colouring agent etc. can be described as excipient, tool
Body to the present invention, it is preferred that excipient of the present invention be wetting agent, dispersant, pH adjusting agent, antioxidant, filler,
Diluent, lubricant, solubilizer, suspending agent, flavouring, adhesive, disintegrant, osmotic pressure regulator, flocculant,
One or more in antiplastering aid, suspending agent, emulsifying agent and preservative, more preferably filler, diluent, lubricant,
One or more in disintegrant, wetting agent and adhesive, it is highly preferred that filler be preferably starch such as pregelatinized starch,
One or more in microcrystalline cellulose, lactose and calcium monohydrogen phosphate；The lubricant is preferably magnesium stearate, talcum powder or two
Silica；One or more in the disintegrant such as dried starch, sodium carboxymethylcellulose and PVPP；The bonding
Agent is preferably the one or more in starch paste, methylcellulose, hydroxy propyl cellulose and gelatin.Pharmaceutical excipient or medicine
It can be screened or be determined by simple experiment according to general knowledge known in this field with the specific species and consumption of carrier.
The pharmaceutical composition of the present invention can be made well known to a person skilled in the art conventionally form, and the preparation method of selection depends on
In expected method of administration.For example, can be in tablet, capsule, microcapsules, pill, micropill as oral administration medicine
Agent, pulvis, sustained release composite, solution, form of suspension；Noted as sterile solution, suspension or emulsion for parenteral
Penetrate；It is used for local administration as ointment or creams or is used for rectal administration as suppository.
Embodiment
Reagent：The reactant and catalyst used in the embodiment of the present invention is that chemistry is pure, can be used directly or passes through as needed
Cross simple purification；Organic solvent etc. is that analysis is pure, is directly used.Reagent is purchased from Chinese Medicine (group) Shanghai chemistry
Reagent Company.
Unbodied lesinurad S configuration axial chirality enantiomers are prepared by preparative liquid chromatograph, i.e., using preparation
Liquid chromatograph, to the progress pair of racemic 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid
Body separation is reflected, unbodied S configurations axial chirality enantiomer is obtained.Instrument：SFC-80(Thar,Waters)；Prepare chiral column
Model：OJ posts 20 × 250mm, 5 μm (Dacel)；Column temperature：35℃；Mobile phase：CO2/ MeOH=75/25, flow velocity：
80g/min；Detection wavelength：214nm；Post pressure：100bar；Sample size：0.2mL；Circulation time：2.5min；Match somebody with somebody
Sample loading mode：The lesinurad of 6000mg racemizations is dissolved in 50mL methanol.It is S types that axial chirality is collected in enrichment
Lesinurad, is concentrated to give amorphous, i.e., (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazoles shown in formula III
- 3- bases sulfenyl) acetic acid.Unbodied lesinurad S configuration axial chirality enantiomers can also be prepared by other method, than
Chemical resolution such as is carried out to raceme, and is not limited to this.
Detection method and instrument：
X-ray diffractometer model：Rigaku D/Max-2550PC,
Test condition：Power 40kV × 250mA, 2 3~40 ° of θ,
Step width (step width)：0.02 °,
Scan mode：Continuous scanning.
Differential scanning calorimetry (DSC) is characterized：
Instrument：TA companies, DSC Q100,
Test condition：Purge gass：Nitrogen 50ml/min, programming rate：10 DEG C/min, temperature range：30~150 DEG C.
Thermogravimetric analysis instrument：TA companies, model SDT Q600,
Test condition：Purge gass：Nitrogen 120ml/min, programming rate：10 DEG C/min, temperature range：30~420 DEG C.
Dynamic water adsorption instrument (DVS)：Model LHH-80SDP, parameter：RH%:80%.
The crystal formation III of embodiment 1 preparation
Amorphous (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid sample 0.2g is taken, is added
In 10mL dimethylbenzene, it is heated to 50 DEG C and dissolves 2 hours, saturated solution is made, stirring is cooled to 10 DEG C of crystallizations or quiet
Crystallization is put, is filtered, 45 DEG C are dried 2 hours, obtain 0.16g (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazoles
- 3- bases sulfenyl) acetic acid crystal formation III samples.
The crystal formation III of embodiment 2 preparation
Amorphous (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid sample 0.2g is taken, is added
The in the mixed solvent of 20mL dimethylbenzene and 1mL hexamethylenes, 50 DEG C dissolve by heating 2 hours, and saturated solution, stirring drop is made
Temperature is to 10 DEG C of crystallizations or stands crystallization, filtering, and 45 DEG C are dried 2 hours, obtain 0.1g (S) -2- (5- bromo- 4- (4- cyclopropyl
Naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid crystal formation III samples.
The crystal formation III of embodiment 3 preparation
Amorphous (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyls) acetic acid sample 0.2g is taken, is added
The in the mixed solvent of 30mL dimethylbenzene and 1mL hexamethylenes, 30 DEG C dissolve by heating 2 hours, and saturated solution, stirring drop is made
Temperature is to 10 DEG C of crystallizations or stands crystallization, filtering, and 45 DEG C are dried 2 hours, obtain 0.16g (S) -2- (5- bromo- 4- (4- rings third
Base naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid crystal formation III samples.
Embodiment 4 draws moist experiment
Take respectively in crystal formation III and amorphous each 50mg, the room temperature environment for being placed in 80% relative humidity, carry out dynamic water suction
Attached (DVS) is tested, and test result is as shown in table 2.
The crystal formation III of table 2 draws moist comparing result with unbodied
The above results show, as a result show：Within 14 days, it is amorphous have draw moist；And crystal formation III is moist almost without drawing.
It can be seen that crystal formation III draws moist small than amorphous, with more stability.
Embodiment 5 prepares pharmaceutical composition
Prepare the medicine of the crystal formation III comprising (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid
Compositions：Using No. 00 capsule, the composition of ratio shown in filling following table.
| Raw material | Mass percent | Addition (mg) |
| Crystal formation III | 60% | 300 |
| Pregelatinized starch | 39% | 195 |
| Magnesium stearate | 1% | 5 |
| Amount to | 100% | 500 |
Pharmaceutical composition preparation method：Pregelatinized starch and (S) -2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazoles -3-
Base sulfenyl) acetic acid crystal formation III powder, by 150 mesh sieve, be then charged into blender, mix 15min, by tristearin
Sour magnesium is added in clutch.Then make Dosator types capsule filling machine that mixture is transferred in No. 00 capsule, obtain 500mg/
The capsule of capsule, batch production.
In addition, it is emphasized that in this specification to previous disclosed document enumerate and discussion is not construed as recognizing that these are believed
Breath is prior art either common knowledge.
Claims (10)
1. the S configuration axles of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid shown in formula III
The crystal formation III of chiral enantiomer：
The X-ray powder diffraction spectrum that it is radiated using CuK α, represented with 2 θ angles at least 6.04 ° ± 0.2 °,
7.88 ° ± 0.2 °, 11.04 ° ± 0.2 °, 15.78 ° ± 0.2 °, 16.36 ° ± 0.2 °, 16.84 ° ± 0.2 °, 18.18 ° ± 0.2 ° and 19.86 ° ± 0.2 °
There is diffraction maximum in place.
2. crystal formation III as claimed in claim 1, it is characterised in that also at least 2 θ values be 10.30 ° ± 0.2 °, 13.44 ° ± 0.2 °,
16.00°±0.2°、17.44°±0.2°、18.98°±0.2°、20.84°±0.2°、21.86°±0.2°、22.98°±0.2°、23.76°±0.2°
With 24.32 ° ± 0.2 ° at there is diffraction maximum.
3. crystal formation III as claimed in claim 1, it is characterised in that its at least 2 θ values be 6.04 ° ± 0.1 °, 7.88 ° ± 0.1 °,
There is diffraction at 11.04 ° ± 0.1 °, 15.78 ° ± 0.1 °, 16.36 ° ± 0.1 °, 16.84 ° ± 0.1 °, 18.18 ° ± 0.1 ° and 19.86 ° ± 0.1 °
Peak.
4. the crystal formation III as described in claim 1 or 3, it is characterised in that also at least 2 θ values be 10.30 ° ± 0.1 °,
13.44°±0.1°、16.00°±0.1°、17.44°±0.1°、18.98°±0.1°、20.84°±0.1°、21.86°±0.1°、22.98°±0.1°、
There is diffraction maximum at 23.76 ° ± 0.1 ° and 24.32 ° ± 0.1 °.
5. crystal formation III as claimed in claim 1, it is characterised in that the fusing point measured by differential scanning calorimetry (DSC)
Summit value is 106.4 DEG C.
6. crystal formation III as claimed in claim 1, it is characterised in that its thermogravimetric analysis (TGA) figure is as shown in Figure 3.
7. a kind of method for preparing the crystal formation III as any one of claim 1-6, comprises the following steps：By amorphous 2- (5-
Bromo- 4- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid S configuration axial chiralities enantiomer add dimethylbenzene, first
The in the mixed solvent of benzene or dimethylbenzene and hexamethylene, in 30~70 DEG C of heating for dissolving, is made saturated solution, and cool crystallization,
Obtain crystal formation III.
8. purposes of the crystal formation III in medicine is prepared as any one of claim 1-6, the medicine is used for treatment group
Knit the abnormal illness of uric acid level.
9. purposes as claimed in claim 8, it is characterised in that the illness is selected from gout, hyperuricemia, reduction blood
Clear uric acid.
10. a kind of pharmaceutical composition, it includes crystal formation III as any one of claim 1-6 as active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610236731.5A CN107298660A (en) | 2016-04-15 | 2016-04-15 | The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610236731.5A CN107298660A (en) | 2016-04-15 | 2016-04-15 | The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107298660A true CN107298660A (en) | 2017-10-27 |
Family
ID=60137463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610236731.5A Pending CN107298660A (en) | 2016-04-15 | 2016-04-15 | The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107298660A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103298796A (en) * | 2010-12-30 | 2013-09-11 | 阿迪亚生命科学公司 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetic acid and uses thereof |
| CN105399694A (en) * | 2015-12-11 | 2016-03-16 | 浙江京新药业股份有限公司 | Axially chiral enantiomers of drug Lesinurad |
| CN105622531A (en) * | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | Axial chiral isomers and preparation method and pharmaceutical application thereof |
-
2016
- 2016-04-15 CN CN201610236731.5A patent/CN107298660A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103298796A (en) * | 2010-12-30 | 2013-09-11 | 阿迪亚生命科学公司 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetic acid and uses thereof |
| CN105622531A (en) * | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | Axial chiral isomers and preparation method and pharmaceutical application thereof |
| CN105399694A (en) * | 2015-12-11 | 2016-03-16 | 浙江京新药业股份有限公司 | Axially chiral enantiomers of drug Lesinurad |
Non-Patent Citations (1)
| Title |
|---|
| 刘崇悌等: "《固体药剂的稳定性》", 31 July 1984, 人民卫生出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520205A (en) | Novel crystal form of lenvatinib mesylate and process for producing the same | |
| JP7253491B2 (en) | Crystal Polymorph of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, and Method for Producing and Application of Same | |
| CN113795490A (en) | Novel crystalline forms of N- (3- (2- (2-hydroxyethoxy) -6-morpholinopyridin-4-yl) -4-methylphenyl) -2 (trifluoromethyl) isonicotinamide as Raf inhibitors for the treatment of cancer | |
| WO2014082354A1 (en) | Crystal form of chidamide, preparation method and use thereof | |
| WO2012055351A1 (en) | A crystal form of nilotinib hydrochloride and preparation method thereof | |
| JP7168447B2 (en) | Crystal forms of bilastine and methods for their preparation | |
| JP2022000451A (en) | Compositions and methods related to pyridinoylpiperdine 5-ht1f agonists | |
| CN106279127B (en) | Afatinib acid-addition salts and its crystal form, preparation method and pharmaceutical composition | |
| EP2542548A1 (en) | Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process | |
| JP6738350B2 (en) | Urate transporter inhibitor sodium salt and its crystalline form | |
| WO2009106997A2 (en) | Amorphous arformoterol l-(+)-tartrate | |
| CN104159584A (en) | Aprepitant L-proline solvates - compositions and cocrystals | |
| CN107266377A (en) | A kind of polymorphic of the axial chirality enantiomer of URAT1 inhibitor | |
| CN107298660A (en) | The crystal formation III of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer | |
| CN103059013B (en) | Crystal formation of Dasatinib monohydrate and preparation method thereof | |
| CN107298659A (en) | The crystal formation IV of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer | |
| JP5042861B2 (en) | Crystalline 1H-imidazo [4,5-b] pyridin-5-amine, 7- [5-[(cyclohexylmethylamino) -methyl] -1H-indol-2-yl] -2-methyl, sulfate (1 : 1), trihydrate and its pharmaceutical use | |
| CN107298658A (en) | The crystal formation V of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer | |
| CN113045554A (en) | Fexotinib crystal form and preparation method thereof | |
| CN107298657A (en) | The crystal formation II of 2- (the bromo- 4- of 5- (4- cyclopropyl naphthalene -1- bases) -4H-1,2,4- triazole -3- bases sulfenyl) acetic acid axial chirality enantiomer | |
| WO2019105359A1 (en) | Crystal form of acalabrutinib, preparation method therefor and application thereof | |
| JP2010520298A (en) | Polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo [c, f] [1,2] thiazepin-11-yl) amino] heptanoic acid S, S-dioxide and their preparation And usage | |
| WO2019211870A1 (en) | Polymorphic forms of ibrutinib | |
| JP2018518515A (en) | Polymorphs of phenylaminopyrimidine compounds or salts thereof | |
| TW201125861A (en) | CDC7 inhibitor salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171027 |
|
| RJ01 | Rejection of invention patent application after publication |